Compare DLB & APGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DLB | APGE |
|---|---|---|
| Founded | 1965 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Multi-Sector Companies | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8B | 4.7B |
| IPO Year | 2004 | 2023 |
| Metric | DLB | APGE |
|---|---|---|
| Price | $61.39 | $83.98 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 13 |
| Target Price | $90.75 | ★ $109.67 |
| AVG Volume (30 Days) | 550.1K | ★ 1.1M |
| Earning Date | 04-30-2026 | 05-11-2026 |
| Dividend Yield | ★ 2.33% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.55 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $6.22 | N/A |
| Revenue Next Year | $3.84 | N/A |
| P/E Ratio | $112.35 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $57.62 | $26.20 |
| 52 Week High | $78.28 | $85.94 |
| Indicator | DLB | APGE |
|---|---|---|
| Relative Strength Index (RSI) | 49.83 | 63.94 |
| Support Level | $60.14 | $73.06 |
| Resistance Level | $67.93 | N/A |
| Average True Range (ATR) | 1.36 | 4.45 |
| MACD | 0.27 | 1.19 |
| Stochastic Oscillator | 82.37 | 91.17 |
Dolby Laboratories Inc. develops technologies that enhance audio and video capture, transmission, and playback, enabling high-quality experiences across movies, TV, music, sports, and more. The company designs and manufactures audio, imaging, accessibility, and related hardware and software mainly for cinema, including digital cinema servers and media encryption and packaging tools. It generates the majority of its revenue by licensing its technology, brand, and patents to device manufacturers and by selling cinema hardware and services. It operates as a single reportable segment, with revenue derived mainly from licensing and, to a lesser extent, from premium cinema technologies, across the United States and international markets.
Apogee Therapeutics Inc is a clinical-stage biotechnology company engaged in advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. . Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.